JP2013512866A - アピコンプレクサＦｅｒｌｉｎ、Ｆｅｒｌｉｎ様タンパク質、及び他のＣ２ドメイン含有タンパク質に基づくマラリアワクチン - Google Patents
アピコンプレクサＦｅｒｌｉｎ、Ｆｅｒｌｉｎ様タンパク質、及び他のＣ２ドメイン含有タンパク質に基づくマラリアワクチン Download PDFInfo
- Publication number
- JP2013512866A JP2013512866A JP2012541362A JP2012541362A JP2013512866A JP 2013512866 A JP2013512866 A JP 2013512866A JP 2012541362 A JP2012541362 A JP 2012541362A JP 2012541362 A JP2012541362 A JP 2012541362A JP 2013512866 A JP2013512866 A JP 2013512866A
- Authority
- JP
- Japan
- Prior art keywords
- ferlin
- protein
- epitope
- apicomplexer
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 91
- 102000056303 Ferlin Human genes 0.000 title claims abstract description 77
- 108700036130 Ferlin Proteins 0.000 title claims abstract description 77
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 75
- 101000933074 Arabidopsis thaliana Protein C2-DOMAIN ABA-RELATED 4 Proteins 0.000 title claims abstract description 57
- 229940124735 malaria vaccine Drugs 0.000 title claims abstract description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 58
- 230000000890 antigenic effect Effects 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims description 45
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
- 241000224016 Plasmodium Species 0.000 claims description 18
- 230000008685 targeting Effects 0.000 claims description 16
- 241000223960 Plasmodium falciparum Species 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 8
- 239000002539 nanocarrier Substances 0.000 claims description 8
- 239000013612 plasmid Substances 0.000 claims description 7
- 241000224017 Plasmodium berghei Species 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 241000223997 Toxoplasma gondii Species 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000005867 T cell response Effects 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 241000223996 Toxoplasma Species 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 101710091045 Envelope protein Proteins 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 101710188315 Protein X Proteins 0.000 claims description 2
- 102100021696 Syncytin-1 Human genes 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000011191 terminal modification Methods 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 201000004792 malaria Diseases 0.000 abstract description 19
- 229960005486 vaccine Drugs 0.000 abstract description 6
- 210000004185 liver Anatomy 0.000 description 32
- 244000045947 parasite Species 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 19
- 239000012634 fragment Substances 0.000 description 18
- 230000002238 attenuated effect Effects 0.000 description 15
- 108010074328 Interferon-gamma Proteins 0.000 description 13
- 238000011161 development Methods 0.000 description 13
- 210000003046 sporozoite Anatomy 0.000 description 13
- 102100037850 Interferon gamma Human genes 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 210000004698 lymphocyte Anatomy 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 108050009459 C2 domains Proteins 0.000 description 6
- 102000002110 C2 domains Human genes 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000004988 splenocyte Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 108091006112 ATPases Proteins 0.000 description 4
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 4
- 241000224482 Apicomplexa Species 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 238000003205 genotyping method Methods 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 102100032912 CD44 antigen Human genes 0.000 description 3
- 108060002716 Exonuclease Proteins 0.000 description 3
- 102000011786 HLA-A Antigens Human genes 0.000 description 3
- 108010075704 HLA-A Antigens Proteins 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 3
- 102100033467 L-selectin Human genes 0.000 description 3
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 101000946719 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Carboxysome assembly protein CcmN Proteins 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
- 102000013165 exonuclease Human genes 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 229940031626 subunit vaccine Drugs 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 238000011510 Elispot assay Methods 0.000 description 2
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 238000011785 NMRI mouse Methods 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 240000004922 Vigna radiata Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000000925 erythroid effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011870 unpaired t-test Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- BPVHBBXCESDRKW-UHFFFAOYSA-N 5(6)-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21.C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BPVHBBXCESDRKW-UHFFFAOYSA-N 0.000 description 1
- 241000256186 Anopheles <genus> Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000009182 Parasitemia Diseases 0.000 description 1
- 240000001857 Phyllostachys elegans Species 0.000 description 1
- 241000223830 Plasmodium yoelii Species 0.000 description 1
- 102400000745 Potential peptide Human genes 0.000 description 1
- 101800001357 Potential peptide Proteins 0.000 description 1
- 241000982698 Prorodonopsis coli Species 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 101000946720 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Carboxysome assembly protein CcmO Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000026502 entry into host cell Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000007620 mathematical function Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 210000003936 merozoite Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- 229960000611 pyrimethamine Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- -1 succinimidyl ester Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26702609P | 2009-12-05 | 2009-12-05 | |
| US61/267,026 | 2009-12-05 | ||
| PCT/EP2010/007399 WO2011066995A1 (en) | 2009-12-05 | 2010-12-06 | Malaria vaccines based on apicomplexan ferlins, ferlin-like proteins and other c2-domain containing proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013512866A true JP2013512866A (ja) | 2013-04-18 |
| JP2013512866A5 JP2013512866A5 (cg-RX-API-DMAC7.html) | 2017-01-26 |
Family
ID=43499977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012541362A Pending JP2013512866A (ja) | 2009-12-05 | 2010-12-06 | アピコンプレクサＦｅｒｌｉｎ、Ｆｅｒｌｉｎ様タンパク質、及び他のＣ２ドメイン含有タンパク質に基づくマラリアワクチン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8968750B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2507259B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2013512866A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102781958B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012013581A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2783107C (cg-RX-API-DMAC7.html) |
| MX (1) | MX2012006458A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011066995A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017210441A (ja) * | 2016-05-26 | 2017-11-30 | 国立大学法人大阪大学 | マラリアワクチン |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012076157A2 (en) | 2010-12-06 | 2012-06-14 | Ruprecht-Karls-Universität Heidelberg | Malaria vaccines based on pre-erythrocytic antigens from p. falciparum |
| ES2847930T3 (es) | 2013-01-07 | 2021-08-04 | Mucosal Vaccine Tech Llc | Vacunas terapéuticas para el tratamiento de las infecciones por el virus del herpes simple de tipo 2 |
| TWI790593B (zh) | 2014-08-19 | 2023-01-21 | 美商默沙東有限責任公司 | 抗tigit抗體 |
| CN108290936B (zh) * | 2015-08-14 | 2022-07-12 | 默沙东公司 | 抗tigit抗体 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09510877A (ja) * | 1994-03-31 | 1997-11-04 | アイシス・イノベーション・リミテッド | マラリアペプチド |
| WO2004037856A2 (en) * | 2002-10-25 | 2004-05-06 | Institut Pasteur | Plasmodium falciparum virulence factor var o |
| WO2004078099A2 (en) * | 2003-03-03 | 2004-09-16 | Pevion Biotech Ltd. | Compositions and methods for the generation of protective immune response against malaria |
| WO2005063804A1 (en) * | 2003-12-30 | 2005-07-14 | Københavns Universitet Panum | Compounds useful in the diagnosis and treatment of malaria |
| WO2009082440A2 (en) * | 2007-12-18 | 2009-07-02 | Vaxinnate Corporation | Compositions of toll-like receptor agonists and malaria antigens and methods of use |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518528A (en) * | 1983-05-19 | 1985-05-21 | Rasnick David W | α Amino fluoro ketones |
| US5198334A (en) * | 1989-07-21 | 1993-03-30 | Terumo Corporation | Protection of natural killer cell cytolytic activity in peripheral blood mononuclear cells |
| JP2001509813A (ja) * | 1997-01-21 | 2001-07-24 | ニューヨーク ユニヴァーシティ | 抗マラリアワクチン用ユニバーサルｔ細胞エピトープ |
| US20030077653A1 (en) * | 2000-04-20 | 2003-04-24 | The University Of Georgia Research Foundation, Inc. | Method for the identification of active site protease inactivators |
| US7811575B2 (en) * | 2001-04-10 | 2010-10-12 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 158P3D2 useful in treatment and detection of cancer |
| GB0210128D0 (en) * | 2002-05-02 | 2002-06-12 | Chiron Spa | Nucleic acids and proteins from streptococcus groups A & B |
| CA2536819A1 (en) * | 2003-08-26 | 2005-03-03 | The Council Of The Queensland Institute Of Medical Research | Immunogenic agent and pharmaceutical composition for use against homologous and heterologous pathogens including plasmodium spp |
| US7951782B2 (en) * | 2005-09-29 | 2011-05-31 | Maruha Nichiro Seafoods, Inc | Composition effective to prevent or treat adult disease |
| GB0601059D0 (en) * | 2006-01-19 | 2006-03-01 | Univ Durham | Target |
| US8343498B2 (en) * | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
| US8277812B2 (en) * | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| US8343497B2 (en) * | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
| WO2011085070A2 (en) * | 2010-01-06 | 2011-07-14 | Virginia Tech Intellectual Properties, Inc. | Methods and compositions to improve the health of plants, animals and microbes by manipulating protein entry into symbionts and their hosts |
| WO2012076157A2 (en) * | 2010-12-06 | 2012-06-14 | Ruprecht-Karls-Universität Heidelberg | Malaria vaccines based on pre-erythrocytic antigens from p. falciparum |
-
2010
- 2010-12-06 CN CN201080063115.5A patent/CN102781958B/zh not_active Expired - Fee Related
- 2010-12-06 BR BR112012013581A patent/BR112012013581A8/pt not_active Application Discontinuation
- 2010-12-06 MX MX2012006458A patent/MX2012006458A/es unknown
- 2010-12-06 JP JP2012541362A patent/JP2013512866A/ja active Pending
- 2010-12-06 WO PCT/EP2010/007399 patent/WO2011066995A1/en not_active Ceased
- 2010-12-06 US US13/513,059 patent/US8968750B2/en active Active
- 2010-12-06 EP EP10787325.9A patent/EP2507259B1/en not_active Not-in-force
- 2010-12-06 CA CA2783107A patent/CA2783107C/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09510877A (ja) * | 1994-03-31 | 1997-11-04 | アイシス・イノベーション・リミテッド | マラリアペプチド |
| WO2004037856A2 (en) * | 2002-10-25 | 2004-05-06 | Institut Pasteur | Plasmodium falciparum virulence factor var o |
| WO2004078099A2 (en) * | 2003-03-03 | 2004-09-16 | Pevion Biotech Ltd. | Compositions and methods for the generation of protective immune response against malaria |
| WO2005063804A1 (en) * | 2003-12-30 | 2005-07-14 | Københavns Universitet Panum | Compounds useful in the diagnosis and treatment of malaria |
| WO2009082440A2 (en) * | 2007-12-18 | 2009-07-02 | Vaxinnate Corporation | Compositions of toll-like receptor agonists and malaria antigens and methods of use |
Non-Patent Citations (10)
| Title |
|---|
| JPN6015004114; Ｔｒｅｎｄｓ ｉｎ Ｐａｒａｓｉｔｏｌｏｇｙ ２４， ２, 2007, ｐ．７４-８４ * |
| JPN6015004117; Ｉｎｆｅｃｔｉｏｎ ａｎｄ Ｉｍｍｕｎｉｔｙ ７５， １２, 2007, ｐ．５９４７-５９５５ * |
| JPN6015004120; Ｐｈｉｌ． Ｔｒａｎｓ． Ｒ． Ｓｏｃ． Ｌｏｎｄ． Ｂ ３５７, 2002, ｐ．２５-３３ * |
| JPN6015004124; Ｓｃｉｅｎｃｅ ３０７, 2005, ｐ．８２-８６ * |
| JPN6015004127; Ｎａｔｕｒｅ ４１９, 2002, ｐ．４９８-５１１ * |
| JPN6015004130; Ｎａｔｕｒｅ ４１９, 2002, ｐ．５１２-５１９ * |
| JPN6015004136; Ｊｏｕｒｎａｌ ｏｆ ｔｈｅ Ｎｅｕｒｏｌｏｇｉｃａｌ Ｓｃｉｅｎｃｅｓ ２６０, 2007, ｐ．１１４-１２３ * |
| JPN6015004138; Ｔｒｅｎｄｓ ｉｎ Ｃｅｌｌ Ｂｉｏｌｏｇｙ １４， ４, 2004, ｐ．２０６-２１３ * |
| JPN6015053142; ＮＣＢＩ［ｏｎｌｉｎｅ］， Ａｃｃｅｓｓｉｏｎ Ｎｏ． ＸＭ＿００１３４８６６８， ＜ＵＲＬ： ｈｔｔｐ：／／ｗｗｗ．ｎｃｂｉ．ｎｌｍ．ｎｉｈ．ｇｏｖ／ｎｕｃｃｏｒｅ／１２４８０９８６３？ｓａｔ＝１３ * |
| JPN7015000319; ＥＭＢＬ／ＧｅｎＢａｎｋ／ＤＤＢＪ ｄａｔａｂａｓｅｓ , 200803 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017210441A (ja) * | 2016-05-26 | 2017-11-30 | 国立大学法人大阪大学 | マラリアワクチン |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2507259B1 (en) | 2016-08-24 |
| BR112012013581A8 (pt) | 2017-12-26 |
| CN102781958B (zh) | 2017-07-11 |
| US8968750B2 (en) | 2015-03-03 |
| MX2012006458A (es) | 2012-09-07 |
| CA2783107C (en) | 2018-08-07 |
| WO2011066995A1 (en) | 2011-06-09 |
| BR112012013581A2 (pt) | 2017-01-10 |
| CN102781958A (zh) | 2012-11-14 |
| CA2783107A1 (en) | 2011-06-09 |
| US20120308598A1 (en) | 2012-12-06 |
| EP2507259A1 (en) | 2012-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Aly et al. | Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection | |
| van Dijk et al. | A central role for P48/45 in malaria parasite male gamete fertility | |
| Sheehy et al. | ChAd63-MVA–vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans | |
| Kaneko et al. | The high molecular mass rhoptry protein, RhopH1, is encoded by members of the clag multigene family in Plasmodium falciparum and Plasmodium yoelii | |
| Bhatia et al. | Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice | |
| US20220111030A1 (en) | Antigen specific multi epitope-based anti-infective vaccines | |
| Haussig et al. | Inactivation of a Plasmodium apicoplast protein attenuates formation of liver merozoites | |
| Montagna et al. | Antigen export during liver infection of the malaria parasite augments protective immunity | |
| Zhao et al. | Chitosan nanovaccines as efficient carrier adjuvant system for IL-12 with enhanced protection against HBV | |
| Aidoo et al. | Field studies of cytotoxic T lymphocytes in malaria infections: implications for malaria vaccine development | |
| JP2013512866A (ja) | アピコンプレクサＦｅｒｌｉｎ、Ｆｅｒｌｉｎ様タンパク質、及び他のＣ２ドメイン含有タンパク質に基づくマラリアワクチン | |
| Nico et al. | Adaptive immunity against Leishmania nucleoside hydrolase maps its C-terminal domain as the target of the CD4+ T cell–driven protective response | |
| Jensen et al. | Molecular and immunological characterisation of the glucose regulated protein 78 of Leishmania donovani | |
| US9314517B2 (en) | Parasite vaccine | |
| Chu et al. | Evaluation of protective immune response induced by a DNA vaccine encoding GRA8 against acute toxoplasmosis in a murine model | |
| de Menezes et al. | Long lived liver-resident memory T cells of biased specificities for abundant sporozoite antigens drive malaria protection by radiation-attenuated sporozoite vaccination | |
| Devender et al. | Immunogenicity and protective efficacy of tuzin protein as a vaccine candidate in Leishmania donovani-infected BALB/c mice | |
| Wu et al. | A novel combined quadrivalent self-amplifying mRNA-LNP vaccine provokes protective immunity against acute and chronic toxoplasmosis in mice | |
| EP2648744B1 (en) | Malaria vaccines based on pre-erythrocytic antigens from p. falciparum | |
| Dou et al. | Novel constructs of tuberculosis gene vaccine and its immune effect on mice | |
| JP5573679B2 (ja) | マラリアワクチン組成物および細胞媒介免疫性を惹起する成分 | |
| Cao et al. | Protective efficacy of Toxoplasma gondii bivalent MAG1 and SAG1 DNA vaccine against acute toxoplasmosis in BALB/c mice | |
| Kongsomboonvech et al. | Variation in CD8 T cell IFNγ differentiation to strains of Toxoplasma gondii is characterized by small effect QTLs with contribution from ROP16 | |
| JP2006151813A (ja) | 細胞内寄生病原体に対する遺伝子ワクチン | |
| Bunkofske et al. | Epitopes in the GPI attachment signal peptide of Trypanosoma cruzi mucin proteins generate robust but delayed and nonprotective CD8+ T cell responses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131113 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150203 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20150305 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150501 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150602 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150703 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160105 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160405 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160705 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161003 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20161205 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170131 |